An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms PIONEER-OLE
- Sponsors MyoKardia
- 11 Nov 2019 Results presented in a MyoKardia Media Release.
- 04 Nov 2019 According to a MyoKardia media release, data from the study has been presented at the European Society of Cardiology Congress 2019.
- 04 Nov 2019 According to an MyoKardia media release, the company will host a conference call on Monday, November 11, 2019 to discuss PIONEER-OLE 48-week data being presented at the upcoming American Heart Association Scientific Sessions 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History